The proliferation-suppressor role of Sirt-3 was confirmed in multiple cancer types, including breast cancer and colon cancer, both in vitro and in vivo [41]; it was also reported that Sirt-3 could inhibit HCC cell growth through reducing Mdm2-mediated p53 degradation [43]. This evidence concerns the gene TP53 and hepatocellular carcinoma.